10-Q: Longduoduo Reports Q3 2026 Results Amidst Revenue Decline

Longduoduo Company Limited reported a significant decrease in revenue for the third quarter of fiscal year 2026, driven by economic headwinds and cautious consumer spending.

Summary

• Total revenue for the three months ended March 31, 2026, was $187,392, a 76% decrease from $777,720 in the same period of 2025.
• For the nine months ended March 31, 2026, total revenue was $1,191,421, a 64% decrease from $3,322,287 in the prior year period.
• The company experienced a net loss of $190,007 for the three months ended March 31, 2026, compared to a net loss of $116,320 for the same period in 2025.
• For the nine months ended March 31, 2026, the net loss was $575,434, a significant increase from a net income of $325,775 for the same period in 2025.
• Cash and cash equivalents decreased to $1,224,881 as of March 31, 2026, from $1,642,721 as of June 30, 2025.
• The company attributes the revenue decline to the prevailing economic environment, characterized by waning consumer confidence and cautious spending on preventive healthcare services.
• Operating expenses decreased by 56% for the three months ended March 31, 2026, and by 38% for the nine months ended March 31, 2026, primarily due to reductions in advertising and promotion, and office expenses.
• The company is implementing plans to improve operations by adjusting operational policies and investing in marketing to revitalize operations.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to the significant revenue decline, shift to a net loss, and material weaknesses in internal controls, despite efforts to reduce operating expenses.

Positives

• Operating expenses were reduced significantly, with a 56% decrease for the three months ended March 31, 2026, and a 38% decrease for the nine months ended March 31, 2026.
• The company is actively adjusting operational policies and investing in marketing to revitalize its operations.
• Deferred revenue increased to $643,317 as of March 31, 2026, from $335,484 as of June 30, 2025, indicating customer prepayments for future services.

Negatives

• Total revenue for the three months ended March 31, 2026, decreased by 76% to $187,392 from $777,720 in the prior year period.
• Total revenue for the nine months ended March 31, 2026, decreased by 64% to $1,191,421 from $3,322,287 in the prior year period.
• The company reported a net loss of $190,007 for the three months ended March 31, 2026, an increase from a net loss of $116,320 in the prior year period.
• The net loss for the nine months ended March 31, 2026, was $575,434, a substantial shift from a net income of $325,775 in the prior year period.
• Cash and cash equivalents decreased by $417,840 for the nine months ended March 31, 2026, to $1,224,881.
• Gross profit from service revenue turned negative (-147% for Q3 2026) due to limited healthcare service volume and equipment depreciation.
• The company disclosed material weaknesses in its internal control over financial reporting, including insufficient segregation of duties, lack of expertise in U.S. GAAP for financial staff, and the CFO's unfamiliarity with U.S. public company requirements.

Risks

• The prevailing economic environment, characterized by waning confidence in economic prospects, has compelled consumers to adopt significantly more cautious spending behavior, curtailing discretionary expenditures on preventive healthcare services and physical examinations.
• The U.S. government's actions and statements regarding U.S.-China relations, including tariffs, sanctions, and enhanced SEC review of China-based operations, could adversely affect the company's ability to raise capital and the market price of its shares.
• Unfavorable government policies on cross-border relations, increased scrutiny of companies with significant China-based operations, capital controls, or tariffs may affect the company's ability to raise capital and the market price of its shares.
• Material weaknesses in internal control over financial reporting could adversely affect the company's ability to record, process, summarize, and report financial information.
• The company's reliance on a single customer for approximately 99.1% of revenue in the nine months ended March 31, 2026, poses a significant concentration risk.
• The company has a significant amount of cash in state-owned banks in China that exceeds insurance coverage, posing a credit risk.

Future Outlook

The company anticipates that future liquidity requirements will arise from the need to fund growth, pay current obligations, and cover future capital expenditures. Primary funding sources are expected to be cash generated from operations and raising additional funds from a public offering and/or debt financing. Management expects continued support from the majority shareholder, Zhang Liang, if needed. However, there is no assurance of sufficient cash flow generation or successful additional financing to remain a going concern.

Management Comments

• Management believes that the government has recently introduced policies to promote economic recovery, but it may take some time for the situation to truly improve.
• The Company will continue to invest heavily in advertising and promotion expenses in the near future with a goal of revitalizing its marketing operations.
• Management believes that the government has recently introduced policies to promote economic recovery, but it may take some time for the situation to truly improve.
• The Company will continue to invest heavily in advertising and promotion expenses in the near future as it continues to revitalize its marketing operations.
• Management has evaluated subsequent events through the date which the consolidated financial statements were available to be issued and found no subsequent events requiring disclosure.
• Based on their evaluation, our Chief Executive Officer and Chief Financial Officer concluded that the Companys system of disclosure controls and procedures was not effective as of March 31, 2026.

Industry Context

StockSavvy.ai notes that Longduoduo's significant revenue decline and shift to a net loss in the reported period align with broader economic trends impacting consumer discretionary spending, particularly in the preventive healthcare sector. The company's reliance on commission revenue from a single partner and its efforts to manage operating expenses are critical strategies in this challenging environment.

Comparison to Industry Standards

• The company's revenue decline of 76% for the quarter and 64% for the nine-month period is significantly steeper than typical year-over-year fluctuations seen in stable healthcare service markets.
• The shift from a net income of $325,775 in the prior year's nine-month period to a net loss of $575,434 in the current period indicates a substantial deterioration in profitability, which is concerning compared to industry peers focused on consistent growth.
• The negative gross margin on service revenue (-147% for Q3 2026) is a critical concern, as most healthcare providers aim for positive and healthy gross margins on their core service offerings.
• The material weaknesses in internal controls, particularly regarding staff expertise in U.S. GAAP and the CFO's familiarity with U.S. public company reporting, are red flags that differentiate Longduoduo from more mature and compliant industry players.

Corporate Governance

Legal Proceedings

• The company is not presently a party to any legal proceedings that, in the opinion of its management, would have a material adverse effect on its business, operating results, financial condition, or cash flows.

Related Party Transactions

• Due from related parties: $310 to Zhou Hongxiao (CEO) as of March 31, 2026. This amount was unsecured, repayable on demand, and bore no interest.
• Due to related parties: $409 to Zhang Liang (majority shareholder) and $2,173 to Xu Huibo (President and Chairman) as of March 31, 2026. These amounts were unsecured, repayable on demand, and bore no interest.

Stakeholder Impact

• Shareholders: The significant revenue decline, increased net loss, and material weaknesses in internal controls are likely to negatively impact shareholder value and investor confidence.
• Employees: Reduced operating expenses, particularly in advertising and promotion, could potentially impact marketing and sales teams. The overall financial performance may affect job security.
• Suppliers: The company's financial performance and cash flow situation could impact its ability to meet payment obligations to suppliers.
• Customers: While not explicitly detailed, a focus on operational adjustments and marketing revitalization may aim to improve customer service and offerings in the long term.

Next Steps

• The company will continue to invest heavily in advertising and promotion expenses to revitalize its marketing operations.
• The company is implementing plans to improve its operations by adjusting its operational policies.

Key Dates

Recommendation

The company's financial performance has significantly deteriorated, marked by a substantial revenue decline and a shift from profit to a considerable net loss. Coupled with material weaknesses in internal controls and a high concentration risk from a single customer, the outlook is unfavorable. While the company is attempting to cut costs and revitalize operations, the current economic climate and internal control issues present significant headwinds, suggesting a sell recommendation for investors.

Keywords

Longduoduo, SEC Filing, 10-Q, Quarterly Report, Healthcare Services, Preventive Healthcare, Commission Revenue, Financial Results, China, Economic Downturn, Revenue Decline, Net Loss, Internal Controls